BerGenBio

Investor Presentation • Oct 1, 2021

BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021

BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021

Bergen, Norway, 01 October 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical need, is pleased to announce that it will deliver an e

-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36[th]

Annual Meeting, taking place online from 10-14 November 2021.

Abstract titles have been announced online at the

SITC (https://www.sitcancer.org/2021/home) website. Details of the presentation

are below.

Title: AXL targeting with bemcentinb restores PD-1 blockade sensitivity

of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of

TCF1[+] CD8 T cells

Author: Rolf A. Brekken et al.

Abstract ID: 602

Full abstracts will be available on the SITC website beginning November 9th at

8:00 AM ET.

-Ends-

Contacts

Martin Olin,

Chief Executive Officer, BerGenBio ASA

ir@bergenbio.com

Rune Skeie,

Chief Financial Officer, BerGenBio ASA

rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer, leukaemia

and COVID-19. A first-in-class functional blocking anti-AXL antibody,

tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is

developing a companion diagnostic test to identify patient populations most

likely to benefit from AXL inhibition: this is expected to facilitate more

efficient registration trials supporting a precision medicine-based

commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com